ENTA at a glance
ENANTA PHARMACEUTICALS INC (ENTA, SEC CIK 1177648) filed its latest 10-K annual report on November 19, 2025, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as August 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2025 (FY2025), ENANTA PHARMACEUTICALS INC (ENTA) reported revenue of $65.3 million (down 3.4% from FY2024) and a net loss of $81.9 million. Diluted EPS was -$3.84.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding ENANTA PHARMACEUTICALS INC (ENTA) shares worth $137.3 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $65.3M
- −3.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $137.3M · +0 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No material changes to risk factors identified in provided text
- Liquidity risk: $211,493 cash, cash equivalents, and marketable securities expected to fund operations for at least 12 months
- Financial risk: Royalty-sale liability $125,073 with 12.8% effective annual imputed interest rate
- Market risk: MAVYRET/MAVIRET royalties depend on AbbVie sales and face competition from other HCV treatments
- Regulatory risk: Product candidates require extensive clinical testing and regulatory approvals before commercialization
AI summary of the ENTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results for quarter ended June 30, 2026
- Earnings details furnished in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q3 revenue $14.4M, down from $18.3M, reflecting lower AbbVie MAVYRET/MAVIRET sales
- Net loss $19.5M, or $0.67 per diluted share, versus $18.3M and $0.85 in Q3 2025
Item 1.01: Entry into a Material Definitive Agreement
- At-the-market equity facility authorizes up to $75 million in common-stock sales
- Jefferies serving as sales agent with commission up to 3.0% of gross proceeds
Item 8.01: Other Events
- Federal Circuit affirmed December 2024 summary judgment invalidating Enanta’s ’953 Patent
- Patent-infringement damages claim against Pfizer over Paxlovid manufacturing, use, and sales effectively defeated
AI summaries of ENTA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ENTA
Don't miss the next ENTA filing
- Alerts as it files. A push when ENTA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ENTA, by share count.
- Ask anything. An AI agent that reads every ENTA filing and answers with sources.
ENTA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Rottinghaus Scott T. | F | Aug 8, 2026 | 1,467 | $13.34 |
| CARTER BRUCE L A | A | Mar 11, 2026 | 20,000 | - |
| FOLETTA MARK G | A | Mar 11, 2026 | 20,000 | - |
| Hata Yujiro S | A | Mar 11, 2026 | 20,000 | - |
| Vance Terry | A | Mar 11, 2026 | 20,000 | - |
| Russell Lesley | A | Mar 11, 2026 | 20,000 | - |
| Peterson Kristine | A | Mar 11, 2026 | 20,000 | - |
| Kowalsky Matthew Paul | A | Feb 12, 2026 | 4,175 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $67.6M | $65.3M |
| Operating Income | - | -$121.7M | -$85.3M |
| Net Income | -$133.8M | -$116.0M | -$81.9M |
| Op. Margin | - | -179.9% | -130.7% |
| Net Margin | - | -171.6% | -125.4% |
| Balance Sheet | |||
| Total Assets | $462.3M | $376.7M | $280.7M |
| Equity | - | $128.8M | $64.7M |
| ROE | - | -90.1% | -126.5% |
| Per Share | |||
| EPS | $-6.38 | $-5.48 | $-3.84 |
| Cash Flow | |||
| Operating CF | - | -$78.8M | -$19.3M |
| CapEx | $9.1M | $17.9M | $12.9M |
Source: XBRL data in ENANTA PHARMACEUTICALS INC (ENTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ENTA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $137.3M |
| Q1 2026 | 26 | $124.0M |
| Q4 2025 | 23 | $151.6M |
| Q3 2025 | 23 | $93.3M |
| Q2 2025 | 25 | $63.3M |
| Q1 2025 | 21 | $37.4M |
| Q4 2024 | 17 | $32.0M |
| Q3 2024 | 17 | $46.4M |
- Goldman Sachs Group+199.6K (+75%)
- BlackRock+140.7K (+5%)
- Dimensional Fund Advisors+79.4K (+39%)
- Vanguard Portfolio Management LLC+62.6K (+7%)
- Vanguard Capital Management LLC+33.7K (+3%)
- Millennium Management−238.1K (-27%)
- Citadel Advisors LLC−211.7K (-81%)
- Two Sigma Investments−196.2K (-73%)
- Invesco Ltd−122.5K (-67%)
- Renaissance Technologies LLC−107.7K (-16%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 178 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ENTA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 10, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 8-K | Jun 18, 2026 | - | Analysis | - |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 8-K | Mar 26, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 4 | Mar 13, 2026 | - | - | - |
| 8-K | Mar 12, 2026 | - | Analysis | - |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 4 | Feb 13, 2026 | - | - | |
| 10-Q | Feb 11, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 9, 2026 | - | - | |
| 4 | Dec 5, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ENTA SEC filings: frequently asked questions
Which institutions hold ENTA stock?
As of June 30, 2026, the largest ENANTA PHARMACEUTICALS INC (ENTA) holders among the 13F filers tracked by SignalX were BlackRock ($47.3 million), Vanguard Capital Management LLC ($17.7 million), Vanguard Portfolio Management LLC ($14.7 million), Millennium Management ($9.4 million), State Street Corp ($8.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ENTA's revenue in fiscal year 2025?
For the fiscal year ended September 30, 2025 (FY2025), ENANTA PHARMACEUTICALS INC (ENTA) reported revenue of $65.3 million (down 3.4% from FY2024) and a net loss of $81.9 million. Diluted EPS was -$3.84. The figures come from the XBRL data in the 10-K.
What did ENTA report in its latest 8-K?
ENANTA PHARMACEUTICALS INC (ENTA) filed an 8-K on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results for quarter ended June 30, 2026.
What are the latest ENTA SEC filings?
ENANTA PHARMACEUTICALS INC (ENTA) filed its latest 10-K annual report on November 19, 2025, a 10-Q quarterly report on August 12, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on August 10, 2026.
What is ENTA's SEC CIK number?
ENANTA PHARMACEUTICALS INC (ENTA)'s SEC Central Index Key (CIK) is 1177648. EDGAR lists every ENTA filing under that number.
Ask anything about ENTA
The research agent reads ENTA's filings, financials, insider trades and 13F holders, then answers with sources.